Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer

Due to a risk of heart failure during HER2 directed therapy in breast cancer, treatment is monitored with imaging of myocardial function, which is resource demanding for both patients and the health care system. The purpose of this study is to evaluate, if biomarkers can replace imaging based examinations of myocardial function during HER2 directed therapy.

Trial Details

NCT ID
NCT05406635
Phase
NA
Sponsor
Odense University Hospital
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Biomarkers: Troponins and natriuretic peptides
Locations (sample)
  • Aalborg, Denmark|57.048,9.9187
  • Copenhagen, Denmark|55.67594,12.56553
  • Herlev, Denmark|55.72366,12.43998
  • Odense, Denmark|55.39594,10.38831

Key Eligibility Criteria

  • Patients with non-metastatic HER2 positive breast cancer
  • Scheduled for standard chemotherapy and HER2 directed therapy with trastuzumab +/- pertuzumab
  • Age \> 18 years
  • Sinus rhythm on ECG

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →